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Metabolic reprogramming is a key hallmark of cancer, but less is known about metabolic 46	
plasticity of the same tumor at different sites. Here, we investigated the metabolic 47	
adaptation of leukemia in two different microenvironments, the bone marrow and the 48	
central nervous system (CNS). We identified a metabolic signature of fatty-acid 49	
synthesis in CNS leukemia, highlighting Stearoyl-CoA desaturase (SCD1) as a key 50	
player. In vivo SCD1 overexpression increases CNS disease, whilst genetic or 51	
pharmacological inhibition of SCD1 decreases CNS load. Overall, we demonstrated that 52	
leukemic cells dynamically rewire metabolic pathways to suit local conditions and that 53	
targeting these adaptations can be exploited therapeutically. 54	
 55	
INTRODUCTION 56	
Metabolic reprogramming is acknowledged as a hallmark of cancer, encompassing the 57	
idea that cancer cells adapt their metabolism to support cell proliferation and to survive 58	
in hypoxic and or nutrient-poor environments1–3. In hematologic malignancies, 59	
harnessing metabolic reprogramming of cancer cells has proven to be clinically useful in 60	
diagnostics such as Positron Emission Tomography and in identification of discrete 61	
subgroups in diffuse large B-cell lymphoma requiring specific therapeutic approaches4,5. 62	
Metabolic vulnerabilities of hematologic malignancies can be potentially exploited 63	
therapeutically6,7. In fact, successes in exploiting metabolic vulnerabilities as a 64	
therapeutic approach have been most notable in acute lymphoblastic leukemia (ALL) 65	
where the use of asparaginase is a cornerstone of most modern treatment protocols, 66	
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targeting the asparagine-dependent leukemic cells8. Despite a recent explosion in 67	
cancer metabolism research, little is known about how metabolism dynamically changes 68	
in cancer cells in response to migration from one tissue compartment to another. Here 69	
we investigated how ALL cells metabolically-adapt to the CNS microenvironment upon 70	
migration from the bone marrow (BM) and tested whether this adaptation can inform 71	
novel targeted therapies for CNS leukemia.  72	
 73	
ALL commonly infiltrates the CNS and successful eradication is essential for long-term 74	
remission9. Indeed, the largest advance in cure rates for ALL patients came with the 75	
introduction of universal CNS-directed therapy in the 1970s10. Although relatively 76	
effective, current CNS-directed therapy in the form of intrathecal and systemic high 77	
dose methotrexate, or less commonly craniospinal irradiation, is associated with 78	
significant neurotoxicity11,12. A lack of mechanistic understanding of CNS leukemia has 79	
hindered the development of targeted, less toxic, therapeutic approaches.  80	
 81	
Early post-mortem histopathology of CNS leukemia identified that blast cells infiltrate 82	
the leptomeninges and generally stay confined within this compartment13. More recent 83	
work using animal models and patient-derived xenografts has identified a generic 84	
property of ALL cells that enables CNS colonization. Previous published work from our 85	
laboratory in mouse and human has established that there is no evidence of a selection 86	
for subclones within the CNS microenvironment although altered expression of certain 87	
genes, such as CCR7, can enhance the process of CNS-entry14–19. It is postulated that 88	
the CNS may act as a “sanctuary site” where leukemic cells are able to evade the 89	
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immune response and be less exposed to systemic chemotherapy9,20. Successful 90	
adaptation to the CNS niche is an essential pre-requisite for long-term survival of 91	
leukemic cells, and for subsequent disease relapse in this extramedullary site. 92	
 93	
Within the CNS niche, ALL cells are bathed in cerebrospinal fluid (CSF) within the 94	
leptomeningeal regions which is poorly vascularized and restricted by the blood-CSF 95	
barrier and therefore poor in nutrients and oxygen21–23. In contrast, sites of systemic 96	
engraftment, such as spleen or bone marrow, are well vascularized and constitute a rich 97	
niche with mesenchymal cells, cytokines and chemokines, favoring leukemic cell 98	
survival and proliferation24–26. Since leukemic blasts need energy and metabolic building 99	
blocks to survive and proliferate, and CSF nutrient supplies are scarce, we 100	
hypothesized that changes in metabolism would take place when ALL engrafts in the 101	
CNS. Using gene expression profiles and metabolic characterizations of leukemic cells 102	
in different niches, followed by gene ablation and pharmacologic manipulation of the 103	
cells, we identified an essential role for the fatty-acid synthesis gene, stearoyl co-A 104	
desaturase (SCD1), in CNS localization. 105	
 106	
RESULTS 107	
CNS-derived ALL cells display a lipid oriented metabolic transcriptional signature 108	
To investigate transcriptional adaptations of ALL to the CNS microenvironment two 109	
human leukemic cell lines, SEM and REH, were used. SEM cells have the t(4;11) 110	
KMT2A-AFF1 (MLL-AF4) chromosomal translocation and REH cells have the t(12;21) 111	
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ETV6-RUNX1 (TEL-AML1) translocation, representing high-risk and standard-risk 112	
subtypes respectively. Cells were transplanted into immunodeficient mice. CNS tropism 113	
was demonstrated for both cell lines and they invaded the leptomeninges in a timeframe 114	
ranging from 4 to 5 weeks (Supplementary Figure 1). At experimental endpoint, blasts 115	
were retrieved from the CNS and periphery (spleen), and their gene expression profiles 116	
were compared using RNA-sequencing (experimental workflow shown in 117	
Supplementary Figure 2A). 118	
 119	
The human SEM cells’ gene expression profiles clustered according to site of 120	
colonization in the transplanted mice; CNS versus spleen (Figure 1A). Differentially 121	
expressed genes were ranked according to adjusted p-values and interestingly, genes 122	
associated with cellular metabolism or stress responses comprised 12 of the top 20 123	
protein-coding genes (Supplementary Figure 2B-I). This was also the case with 124	
transplanted REH cells, where 14 of the top 20 genes where associated with 125	
metabolism or stress response (Supplementary Figure 2B-II), supporting our 126	
hypothesis that metabolic adaptation is a key feature of successful CNS engraftment. 127	
Further analysis using gene set enrichment algorithms (GSEA) identified positive 128	
correlation of lipid and lipoprotein metabolism signatures in CNS-derived cells, with 129	
particular propensity towards fatty acid synthesis (Figure 1B I and III). On the other 130	
hand, oxidative phosphorylation processes, linked to fatty acid degradation, were 131	
negatively correlated with CNS involvement and enriched in SEM cells from the spleen 132	
of transplanted mice (Figure 1B II-III). The same pattern was observed in mice 133	




CSF is a fatty acid-poor compartment compared to the plasma 136	
CNS leukemic blasts are surrounded by the CSF. Since the strongest metabolic 137	
signature reported above indicated that de novo fatty acid and lipid synthesis is 138	
upregulated when ALL cells reach the CNS, we analyzed the fatty acid content of the 139	
CSF to understand this transcriptional adaptive response. The fatty acid content of 140	
normal CSF and plasma from both non-leukemic humans and mice was characterized 141	
by mass spectrometry (Figure 1C-D). In both species, fatty acids are scarce in the CSF 142	
compared to plasma. This suggests that ALL cells require to perform de novo synthesis 143	
of fatty acids rather than rely on exogenous supply, in order to support their survival and 144	
proliferation in the CNS. Mass spectrometric analysis of mouse CSF demonstrated that 145	
all metabolic precursors for fatty acid synthesis are present in comparable levels to 146	
those in plasma (Table 1), as observed in humans (Supplementary table 1). 147	
Furthermore, precursors for fatty acid synthesis were also present in the CSF even in 148	
the presence of leukemic infiltration (Table 1). 149	
 150	
SCD1 is highly expressed in human CNS leukemic blasts 151	
Lipid anabolism is a pivotal cellular process converting nutrients into building blocks for 152	
membrane biogenesis and for generating signaling molecules. The main lipid metabolic 153	
genes and pathways, for both fatty acid synthesis and degradation, are depicted in 154	
Supplementary Figure 3. To examine if upregulation of de novo fatty acid synthesis, 155	
was a generic adaptation to the CNS microenvironment in ALL, we expanded our 156	
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investigation to primary patient samples and additional ALL cell lines. Expression levels 157	
of a panel of genes were measured by qPCR in blasts collected from CNS and spleen 158	
of mice transplanted with 5 ALL patient-derived samples (3 with t(12;21) ALL and 2 with 159	
t(4;11)) (Figure 2A). Further validation was obtained from an independent cohort of 160	
mice transplanted with REH and SEM cells (Supplementary Figure 4A) and with a 161	
third transplanted human cell line, 018z with known high CNS-tropism9,27 162	
(Supplementary Figure 4B). Furthermore, analysis of two publicly available gene 163	
expression datasets from ALL patients14,15 confirmed a lipid biosynthetic signature in 164	
CNS ALL compared with bone marrow (Figure 2B, Supplementary Figure 5). The first 165	
dataset compared ALL cells from patients with CNS relapse to ALL cells from the bone 166	
marrow at diagnosis and after relapse (GSE60926)15.The second dataset compared 167	
primary samples xenografted in mice and collected from the CNS or bone marrow 168	
(GSE89710)14. Altogether, our results derived from cell lines and patients confirmed 169	
upregulation of genes involved in fatty acid synthesis and downregulation of oxidative 170	
phosphorylation genes in the CNS. In particular, SCD1 was consistently and strongly 171	
upregulated in all data sets (Figures 2A-B and Supplementary Figures 4A-B). 172	
Furthermore, SCD1 protein levels were high in 018z and SEM cells derived from the 173	
CNS compared to bone marrow derived cells (Figure 2C and Supplementary Figure 174	
4C).  175	
 176	
Increased SCD1 expression enhances CNS infiltration in ALL  177	
SCD1 is responsible for the generation of mono-unsaturated fatty acids via the addition 178	
of a double bond in the 9th position of extracellular-derived and de novo synthesized 179	
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saturated fatty acyl-CoAs. This leads to sequential synthesis of different classes of fatty 180	
acids, eventually resulting in either triglyceride storage in lipid droplets or phospholipid 181	
production for biomass (Supplementary Figure 3). Interestingly, our analysis of the 182	
fatty acid composition of the CSF demonstrated that it is very low in fatty acids in 183	
general and extremely poor in oleic and palmitoleic acids, the main products of SCD1 184	
(Figure 1C-D). Given the requirement to overcome a lipid poor microenvironment, we 185	
hypothesized that increased SCD1 expression would provide a relative growth or 186	
survival advantage to the cells in the CNS. To test whether upregulation of SCD1 187	
supports CNS leukemia tropism, we overexpressed SCD1 in leukemic cells. SCD1 188	
overexpression in 018z cells was confirmed by qPCR and immunoblotting (Figure 3A-189	
B). Relative SCD1 activity in cells was assessed by the ratio of mono-unsaturated fatty 190	
acyl-CoAs to their saturated precursors, i.e. the ratio of oleoyl-CoA to stearoyl-CoA and 191	
the ratio of palmitoleoyl-CoA to palmitoloyl-CoA. The ratio between these mono-192	
unsaturated to saturated fatty acyl-CoAs increased in the SCD1 overexpressing 018z 193	
cells, confirming increased SCD1 activity (Figure 3C I-II). The increased ratio of 194	
unsaturated/saturated fatty acyl-CoAs in SCD1 overexpressing cells mirrored the ratio 195	
of these fatty acids either as free fatty acids or as lipid esterified pools (Supplementary 196	
Figure 6A-B). 197	
 198	
In vivo, mice transplanted with SCD1-high 018z cells demonstrated significantly 199	
increased disease burden in the CNS but not in the bone marrow or spleen at 200	
experimental endpoint (Figure 3D). This correlated with a faster onset of CNS disease 201	
manifested by a clinical phenotype of earlier hind limb paralysis compared to controls 202	
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(day 15 in SCD1-high cells as opposed to day 18-21 in control cells – Supplementary 203	
Video 1). Analysis of free fatty acids ratios in the CNS-engrafted cells demonstrated 204	
increased SCD1 activity in overexpressing vs. control 018z cells (Supplementary 205	
Figure 7A). 206	
 207	
SCD1 overexpression in REH cells with generally lower propensity for CNS tropism 208	
(Supplementary Figure 7B) also induced rapid CNS engraftment at 3 weeks, a time at 209	
which control REH cells do not invade the CNS (Figure 3E). Mice transplanted with 210	
SCD1-high REH cells showed the same phenotype of earlier hind limb paralysis and 211	
accumulation of leukemic cells in the CNS seen with the more naturally CNS-tropic 212	
018z cells. Control REH transplanted mice did not show any CNS engraftment at 3 213	
weeks. SCD-1 high REH cells also showed a less pronounced but statistically 214	
significant increase in spleen tumor load and comparable tumor load in the bone 215	
marrow (Figure 3E). 216	
 217	
To directly test if high SCD1 expression confers a competitive advantage to the 218	
formation of CNS ALL we labelled the SCD1-high 018z cells with GFP and the control 219	
018z cells with either GFP or mCherry. While GFP expression in control cells did not 220	
provide any advantage in CNS colonization compared to control cells expressing the 221	
mCherry, the GFP-labelled SCD1-high cells showed a clear competitive advantage in 222	




SCD1 inhibition decreases CNS leukemia burden 225	
As SCD1 controls a key step in fatty acid synthesis, we hypothesized that blocking the 226	
activity of the enzyme would impair ALL survival and/or proliferation in the lipid-deprived 227	
CNS microenvironment. CRISPR/CAS-9 technology was used to ablate SCD1 in CNS-228	
tropic 018z cells. Several guide RNAs were screened and gRNA4 resulted in the most 229	
pronounced decrease in SCD1 protein (Figure 4A) consistent with decreased mRNA 230	
transcripts (Figure 4B). To examine if SCD1 affects cell growth in lipid poor 231	
environments similar to the CSF, we cultured the cells in media containing delipidated 232	
serum. Delipidation itself did not affect the concentration of common nutrients in the 233	
serum (Supplementary Figure 8). SCD1-low cells cultured in medium supplemented 234	
with the delipidated serum showed decreased proliferation compared with cells cultured 235	
in full medium, while proliferation of control cells was not affected (Figure 4C). A 236	
significant decrease in the oleoyl-CoA to stearoyl-CoA ratio, and palmitoleoyl-237	
CoA/palmitoyl-CoA ratio (Figure 4D I-II) indicated that SCD1 enzymatic activity was 238	
indeed decreased in SCD1-low cells. The decrease in the ratio of monounsaturated 239	
fatty acyl-CoAs to their saturated precursors reflected the decreased ratios of free and 240	
lipid esterified fatty acids following SCD1 downregulation (Supplementary Figure 6C-241	
D). 242	
 243	
Importantly, the tumor load in the CNS was significantly decreased in mice engrafted 244	
with SCD1-low cells compared to control (Figure 4E). This was not associated with a 245	
general decline in biological fitness of the cells as decrease in cell number was not 246	
consistent among all tissues, as indicated by an elevated engraftment of SCD1-low cells 247	
11	
	
in the bone marrow compared with the control. Clonal escape from SCD1 248	
downregulation in the bone marrow was excluded by measuring SCD1 protein 249	
expression in leukemic cells engrafting the bone marrow, which confirmed ongoing 250	
suppression (Figure 4F). 251	
 252	
To further confirm the dependency on SCD1 under lipid deprived conditions using a 253	
pharmacologic approach, 018z cells were cultured in lipid rich or lipid deprived 254	
conditions in the presence or absence of the SCD1 inhibitor SW20366828. While the 255	
inhibitor caused a slight decrease in proliferation of control cells in full serum, the effect 256	
of SCD1 inhibition was more pronounced when cells were cultured in delipidated serum 257	
(Figure 5A-D). This decrease in cell number was mitigated in SCD1 overexpressing 258	
cells (Figure 5A, 5C) and as expected, SCD1 inhibition showed minimal or no effect in 259	
SCD1-low cells (Figure 5B, 5D). 260	
 261	
In order to explore whether SCD1 inhibitors could be a therapeutic option to prevent 262	
CNS relapse, we treated transplanted mice with the above mentioned SCD1 inhibitor. 263	
To better monitor the localization of engrafted cells, 018z cells were transduced with a 264	
lentivirus expressing the luciferase reporter gene. Following transplantation, mice were 265	
treated with SCD1 inhibitor for 10 days after which bioluminescent imaging was used to 266	
assess leukemic burden. This was followed by CNS and bone marrow blast counts as 267	
before. Both whole-body imaging and assessment of blasts in different tissue sites 268	
demonstrated a general impairment of 018z engraftment in transplanted mice (Figure 269	
5E), decreasing the tumor load both in the bone marrow and CNS (Figure 5F-G). It 270	
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should be noted however that the decrease in disease burden was greater in the CNS 271	
(88.31% decrease) than the bone marrow (47.21% decrease). 272	
 273	
Moreover, we extended our experiments to primary ALL samples (patient-derived 274	
xenografts – PDXs). We selected 4 PDXs with variable but overall fast and aggressive 275	
CNS phenotype (PDXs features are summarized in Supplementary Table 2). 276	
Treatment with SW203668 (20 mg/kg-daily) started 1 week after the transplant. The 277	
treatment was not associated with systemic toxicity as confirmed by no changes in body 278	
weight of treated mice (Supplementary Figure 9). At sacrifice, treated mice from all 279	
PDX groups showed a consistent reduction in CNS tumor load compared with 280	
respective vehicle control groups, though not all reached statistical significance (Figure 281	
6A-D). Importantly, in all PDX models, the first mouse to reach endpoint with signs of 282	
sickness was from the vehicle treated group. In 3 of the 4 PDX groups (PDXs 1, 3, 4) 283	
there was no significant effect on BM engraftment (Figure 6A, 6C-D), while PDX 2 284	
showed increased BM tumor load upon SCD1 inhibitor treatment (Figure 6B), similar to 285	
the effect observed in 018z SCD1-low model (Figure 4E). Taken together, these results 286	
confirm that CNS leukemia is sensitive to SCD1 pharmacological inhibition pointing to 287	
SCD1 inhibition as a specific therapeutic strategy. 288	
 289	
DISCUSSION 290	
Metabolic adaptation to environmental settings is a key hallmark of cancer, and 291	
therefore is potentially exploitable therapeutically. In this work, we used leukemic cells 292	
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residing in the bone marrow and CNS to investigate metabolic changes occurring in a 293	
single cancer in two different compartments in vivo. These two regions are substantially 294	
different in their nutrient availability in general and fatty acid availability in particular.  295	
 296	
Optimal management of CNS leukemia remains a clinical challenge with current 297	
treatments producing high levels of neurotoxic side effects and lacking efficacy in a 298	
subset of patients. An understanding of the mechanism by which leukemic blasts 299	
survive in the nutrient poor CNS is an important step to designing targeted therapies 300	
with improved toxicity profiles. Work to date using preclinical models has identified that 301	
CNS entry of leukemic blasts is relatively unrestricted and that survival in this hostile 302	
environment is likely to be the key determinant of relapse risk9,17,29. Therefore, we 303	
investigated adaptations of leukemic blasts to the CNS niche in order to identify 304	
potential vulnerabilities.  305	
 306	
Our transcriptional data show that leukemic adaptation to the CNS is primarily metabolic 307	
with alterations in fatty acid synthetic pathways being particularly prominent. The SCD1 308	
gene was identified as a consistently upregulated target in several complementary 309	
datasets. These findings are supported by the very low levels of fatty acids in CSF 310	
compared to plasma. Fatty acids are used by the cells catabolically for oxidation in 311	
order to generate energy, and anabolically, to produce triglycerides, phospholipids, and 312	
cholesterol esters, which serve as important sources of structural components and 313	
biomass. Monounsaturated fatty acids can either be taken up from the environment or 314	
produced de novo in a process involving SCD1.	 Interestingly, cancer cells under 315	
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hypoxic conditions tend to bypass SCD1 and preferably import fatty acids30. While the 316	
CSF is relatively low in oxygen, it is also an extremely poor source of fatty acids, so 317	
cancer cells in the CSF may have a particular dependence on de novo synthetic 318	
pathways. 319	
 320	
Upregulation of SCD1 expression has been reported in primary tumors in breast31, 321	
lung32, kidney33, gastrointestinal tract34 and prostate35 as well as chronic myeloid 322	
leukemia36 and B-cell lymphoma5,15,37. Our findings in ALL are strongly supported by a 323	
recent study investigating potential biomarkers for risk of CNS relapse15 which identified 324	
upregulated SCD1 and osteopontin expression in bone marrow blasts of patients who 325	
went on to experience a CNS relapse. Our work demonstrates a direct functional role 326	
for SCD1 in the CNS microenvironment mechanistically linked to the reduced availability 327	
of fatty acids in CSF compared to plasma. 328	
 329	
SCD1 inhibitors have been developed by the pharmaceutical industry primarily for 330	
treatment of steatohepatitis and obesity. However, interest has increased recently in 331	
their use as anti-cancer agents38. Using a systems biology approach to predict selective 332	
drug targets on the basis of cancer metabolic networks, a specific dependence of 333	
cancer cells on lipid metabolism enzymes was identified39. This model predicted that 334	
targeting enzymes involved in these processes should selectively interfere with the 335	
growth of cancer cells without overt toxicity towards normal tissues. There is evidence 336	
of pre-clinical efficacy in a variety of tumor models, including Burkitt lymphoma and 337	
acute myeloid leukemia37. Although previous studies have reported side effects in 338	
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mouse models40,41, including eye mucosal dysfunction, squinting and skin barrier 339	
dysfunction, they can be considered of less clinical severity compared to the wide 340	
spectrum of severe symptoms associated with commonly used chemotherapeutic 341	
agents such as heart failure and broader systemic toxicity. Of note, we did not detect 342	
any gross toxic effects in mice treated with SW203668. Therefore, the potential benefits 343	
of SCD1 anti-cancer properties may outweigh their risk of side effect. 344	
 345	
Another possible concern is the potential adaptive metabolic rewiring of cancer cells to 346	
circumvent metabolic inhibitors. For example, a recent study identified activation of an 347	
alternative desaturation pathway from palmitate to sapienate in response to SCD1 348	
inhibition in hepatocellular carcinoma cells42. There is also evidence that activation of 349	
autophagy may act as a resistance mechanism for SCD1 inhibition in colorectal cancer 350	
cell lines43. This suggests that multi-drug approaches may be needed to prevent 351	
compensatory “re-wiring” in the face of metabolic inhibitors.  352	
 353	
Importantly, several lines of evidence from other works suggested that the metabolic 354	
adaptations we observed in the CNS are not “hardwired” as genetic mutations or 355	
selection of clones with pre-existing high levels of expression17,29. Rather, they are 356	
reversible adaptive changes to a novel microenvironment. This of course raises the 357	
possibility that cells may also be able to escape SCD1 inhibition by moving to a new 358	
microenvironment rich in exogenous lipids. Indeed, this may explain the variable effect 359	
of SCD1 inhibition on leukemic cells in the BM (Figure 6). Nevertheless, the bone 360	
marrow disease burden can be dealt with using other therapeutic approaches, while the 361	
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SCD1 inhibition might be used to eliminate CNS involvement. The degree of dynamic 362	
movement in and out of the CNS by leukemic blasts is currently unknown. However, in 363	
childhood ALL, CNS relapse is rarely truly “isolated” and sub-microscopic bone marrow 364	
involvement is detected with sensitive molecular techniques in the majority of cases44. 365	
 366	
The concept of metabolic heterogeneity in tumors until now has mainly focused on three 367	
areas. Firstly, the influence of different tumor-initiating genetic lesions in the same 368	
primary cancer type5,45. Secondly, differences between solid tumors originating in 369	
different tissues e.g. lung vs. breast45. Thirdly, the influence of local hypoxia or 370	
differences in nutrient availability as tumors enlarge in their primary sites46. All of these 371	
local effects can “prime” tumors to develop drug resistance or develop capacity to 372	
metastasize to distant sites47,48. In this paper, we highlight a fourth area – metabolic 373	
plasticity demonstrated by cancer cells when entering a new tissue microenvironment. 374	
This has important implications for therapeutic targeting of metabolism in the setting of 375	
metastatic disease or disseminated hematological malignancies and supports the use of 376	
multi-agent therapy. Moreover, it adds a further layer of complexity to the already 377	
recognized issue of intra-tumoral genetic heterogeneity49.		378	
	379	
METHODS 380	
Cell culture  381	
REH [t(12;21) ETV6-RUNX1 (TEL-AML1)] and SEM [t(4;11) KMT2A-AFF1 (MLL-AF4)] 382	
cell lines were bought from ATCC. 018z [(47, XY, +8, del(9)(p13))], were a kind gift of 383	
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Dr. L.H. Meyer from Ulm University. 018z cells were maintained in RPMI supplemented 384	
with 20%FBS, L-glutamine 2mM, non-essential amino acids (0.1 mM glycine, L-alanine, 385	
L-asparagine, L-aspartic acid, L-glutamic acid, L-proline, L-serine) (Gibco-BRL), and 386	
sodium pyruvate 1 mM (Sigma). REH and SEM cells were maintained in Glutamax 387	
25mM glucose Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 388	
(vol/vol) FBS (Life Technologies), 1% penicillin/streptomycin solution. Cells were 389	
cultured at 37°C at 21% oxygen in a 5% CO2 incubator and were regularly monitored for 390	
mycoplasma contamination. Unless otherwise stated, all cell culture reagents were 391	
purchased from Thermo Fisher Scientific (Life Technologies). 392	
 393	
SCD1 Knockout  394	
CRISPR/Cas9 technology was used to knockout SCD1. Exon 3 of the SCD1 gene was 395	
targeted by designing guide RNAs (gRNA) using the publicly available software tool 396	
(crispr.mit.edu:8079/). Seven top-scored gRNAs were cloned into 397	
pLentiCRISPR.EFS.GFP (Addgene plasmid #57818, a gift from Benjamin Ebert, 398	
Division of Hematology, Department of Medicine, Brigham and Women’s Hospital, 399	
Harvard Medical School, Boston) according to published protocols50. Following cloning, 400	
plasmids were transformed into compatible stable bacteria. Single colonies were picked, 401	
and extracted plasmids were sequenced. For efficiency validation, a surveyor assay 402	
was performed using GUIDEIT validation kit (Clontech Laboratories) and the most-403	
efficient gRNA was selected for virus production (Strand guide sequence: 5’-404	
GGCCGAGCTTTGTAAGAGCGG-3’). 018z cells were then transduced and 3 days later 405	
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were sorted for GFP and seeded for 7 days, with media changes every 72 hours. The 406	
scramble vector (pLentiCRISPR.EFS.GFP) was used as the control vector. 407	
 408	
Verification of Endogenous SCD1 Gene Editing 409	
Cells were transduced with the pLentiCRISPR.EFS.GFP construct targeting SCD1. 410	
Cells positive for GFP were sorted and cultured for 7 days. Genomic DNA was 411	
extracted from the sorted population and from wild type 018z cells with the QIAamp 412	
DNA Mini Kit (Quiagen), and CRISPR target regions amplified using appropriate locus-413	
specific primers (FW: 5’-AGCCTGACGAAGACAGTTTCT-3’; REV: 5’-414	
TGCTTTATGGACTTAAGGACTG-3’). Standard PCR conditions were used with Taq 415	
Ready mix (HyLabs) and 100 ng of genomic DNA per the manufacturer’s instructions for 416	
35 cycles. The correct size of the PCR product was checked by agarose gel 417	
electrophoresis. PCR products were then purified with Wizard SV Gel and PCR Clean-418	
Up System Protocol (Promega) and then Sanger-sequenced. RNA was extracted from 419	
018z cells after sorting using Direct-zol RNA MiniPrep Kit (Zymo Research) and cDNA 420	
was synthesized using qScript cDNA Synthesis Kit. CRISPR target regions amplified 421	




Cloning of SCD1 gene was performed with standard cloning protocols. All fragments 426	
amplifications were carried out using Phusion High-Fidelity PCR Master Mix 427	
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(Finnzymes, Espoo, Finland) in touchdown PCR program to account for different 428	
melting temperature of primers. Amplified fragments were purified directly from PCR 429	
reaction using the Wizard SV Gel and PCR Clean-up System (Promega). Fragments 430	
and vectors were digested using restriction enzymes according to manufacturer’s 431	
protocols (NEB Ipswich, MA) and purified after gel electrophoresis using the Wizard SV 432	
Gel and PCR Clean-up System (Promega). Quick ligation kit (NEB Ipswich, MA) was 433	
used to ligate the vectors and inserts. The ligations were transformed to NEB 5-alpha F' 434	
Iq Competent E. coli suitable for toxic genes (NEB Ipswich, MA) according to the 435	
manufacturer’s protocol.  436	
 437	
pCDH-EF1a-MCS-T2A-copGFP vector was purchased from SBI system biosciences 438	
(Mountain View, CA) to allow for efficient bi-cistronic expression51. SCD1 previously 439	
cloned from cDNA was amplified with primers carrying restriction enzymes sequences 440	
as following: NheI for 5’ amplification (5'-441	
GCTAGCGCCACCATGCCGGCCCACTTGCTG-3’) and Bam HI for 3’ amplification (5'-442	
GGATCCGCCACTCTTGTAGTTTCCATC-3’). Purified inserts and the pCDH-EF1a-443	
MCS-T2A-copGFP vector were digested and with NheI and BamHI restriction enzymes 444	
and ligated to form pCDH-EF1a-SCD1-T2A-copGFP. The backbone of the vector 445	





Primary patient material was obtained from approved biobanks. ALL live cells from 449	
diagnosis – Bloodwise Childhood Leukaemia Cell Bank, normal control CSF – Glasgow 450	
Neuroimmunology Biobank, ALL patient CSF – West of Scotland CSF Biobank, plasma 451	
– NHS Greater Glasgow & Clyde Bio-repository. Use of biobanked human samples for 452	
this specific project was approved by the West of Scotland Research Ethics Service (ref 453	




JAX NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG; Charles River Laboratories, Harlow, 458	
United Kingdom) mice were kept in sterile isolators with autoclaved food, bedding, and 459	
water. Xenotransplants were performed in 6-10 weeks old mice, the experimental 460	
protocol varied according to the model, with details given in Supplementary Table 3. At 461	
the end of experiment, mice were sacrificed by overdose of pentobarbital (IP) and cells 462	
were collected from bone marrow, spleen and leptomeninges as previously described17. 463	
For RNA sequencing leukemic cells were purified using a Ficoll gradient (Lymphoprep, 464	
Stemcell) following the supplier instructions. Purity was determined using flow 465	
cytometry. Cells were dry pelleted and snap frozen for further use (see below). For 466	
SCD1 overexpression and inhibition experiments bone marrow, spleen and 467	
leptomeningeal cells were analyzed to check human engraftment by FACS using 468	
Absolute counting beads (Beckman Coulter). GFP was used to identify human cells. 469	
The tumor load was expressed as total amount of leukemic cells in each organ. 470	
Competition assays were performed by transplanting SCD1 overexpressing and control 471	
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cells in the same mouse in a 1:1 ratio (1.25x106 cells/type, total 2.5x106 cells/mouse). 472	
Patient’s samples (PDXs) were expanded in NSG mice and experiments were 473	
performed upon secondary-tertiary passage in the mice. 1x106 cells from donor mice 474	
(90% human engraftment) were transplanted in recipients to perform the experiments. 475	
 476	
All animal experiments were approved by Institutional Ethical Review Process 477	
Committees and were performed under UK Home Office license (PPL 60-4512), Israel 478	
Institutional Animal care and use committee approval (1074/16/ANIM) and Institutional 479	
Animal Care and use Committee at Memorial Sloan Kettering Cancer Center (protocol 480	
11-10-025). 481	
 482	
FBS delipidation using fumed silica 483	
The protocol for delipidation of FBS was adapted from Agnese et al. (1983)52. Lipid 484	
depletion was achieved by adding two grams of fumed silica (Sigma Aldrich) to 100 mL 485	
of FBS, and the suspension was stirred for 2h30. Centrifugation at 5000 rpm for 35 486	
minutes, at room temperature. The supernatant was filtered through a 0.45 µm filter at 487	
first, and then through a 0.22 µm filter. 488	
 489	
In vitro treatment with the SCD1 inhibitor SW203668 490	
At day 0, 0.5x106 cells were seeded in RPMI supplemented with lipidated or delipidated 491	
FBS. A concentration of 1 µM of the SCD1 inhibitor SW203668 or of the vehicle 492	




In vivo treatment with the SCD1 inhibitor SW203668 495	
Ten 6-week old NSG females were transplanted with 1.5x106 GFP+mCherry+FFLuc+ 496	
018z cells. Treatment started 24 hours after transplantation with five mice receiving 497	
vehicle (10% DMSO+ 10% Kolliphor (Sigma Aldrich) + 80% lactic acid pH 5.5) and 5 498	
other mice receiving the small molecule SCD1 inhibitor SW203668 (Cayman Chemical) 499	
at 20 mg/kg twice a day I.P. for 10 days. In vivo bioluminescence assay (IVIS Lumina 500	
LT, Series III, Caliper Life Sciences) was performed at day 10, immediately before 501	
sacrifice. Secondary and tertiary PDXs were transplanted into 6 weeks old NSG female 502	
mice at a dose of 1x106 cells. The treatment with 20 mg/kg SW203668 started 1 week 503	
after the transplant. Mice were sacrificed when they showed the first signs of sickness. 504	
Details on time of treatment for each PDX are displayed in Supplementary Table 3. 505	
Bone marrow, spleen and meninges were collected post-mortem and analysed to check 506	
human engraftment by FACS using absolute counting beads (Beckman Coulter). GFP 507	
expression was used to identify human cells. The tumor load was expressed as total 508	
amount of leukemic cells in each organ. 509	
 510	
SCD1 intracellular staining 511	
Cells isolated from bone marrow and CNS of mice transplanted with human leukemic 512	
cells were fixed with PFA 1.6% and permeabilized with ice-cold 90% methanol. GFP 513	
was used to gate on human cells. Rabbit anti human monoclonal SCD1 antibody (SCD1 514	
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(C12H5) Rabbit mAb #2794, Cell Signaling) was used at a dilution of 1:50 in PBS for 20 515	
minutes at 4°C. 516	
 517	
Western blot 518	
SCD1-high and low cells were cultured in RPMI supplemented with 20% FBS and 519	
harvested in PBS, then pelleted and lysed in CelLytic™ MT Cell Lysis Reagent (Sigma 520	
Aldrich) supplemented with complete mini protease cocktail (11836153001 Roche) and 521	
phosphatase inhibitor cocktail (200-664-3 Sigma Aldrich).	Cells were incubated on ice 522	
for 30 minutes before clarification. Standard procedures were used for western blotting. 523	
Fifty µg of total protein lysate were loaded on a 12% Polyacrylamide gel and incubated 524	
overnight with rabbit anti-human monoclonal SCD1 antibody 1:2000 (SCD1 (C12H5) 525	
Rabbit mAb #2794, Cell Signaling) and vinculin (Vinculin Antibody #4650, Cell 526	
Signaling) at 4°C. Proteins were detected using ECL Western Blotting Substrate 527	
(Promega). 528	
 529	
CSF and plasma sampling from mice 530	
CSF was collected from mice under terminal anesthesia with pentobarbital. A 25-gauge 531	
needle was percutaneously inserted into the cisterna magna and CSF collected by 532	
gravity. Blood was collected immediately post-mortem. Both CSF and blood were 533	
centrifuged at 2,000g for 15 min at 4°C. CSF supernatant and plasma were snap-frozen 534	




Gas Chromatography/Mass Spectrometry analyses 537	
CSF or plasma samples were precipitated vol/vol with ice-cold glacial MetOH (15min, -538	
20°C), followed by ice-cold glacial chloroform extraction (ratio 1:3). After centrifugation 539	
(13,000rpm, 5min), the chloroform fraction was extracted into GC-MS glass vials 540	
(Agilent). Samples were dried under nitrogen and stored at -20°C for subsequent use. 541	
On the day of analysis, samples were re-suspended in chloroform/MetPrepII solution to 542	
generate fatty acid methyl esters (FAMEs). Samples were analyzed using an Agilent 543	
7890B GC system coupled with an Agilent 7000 Triple Quadrupole mass spectrometer. 544	
Phenomenex ZB-1701P columns (30 m × 0.25 mm × 0.25 µm) were used for FAME 545	
separation. Further details are given in Supplementary Table 4. Generated data files 546	
were pre-processed with Agilent Mass Hunter B.06.00 software and relative intensities 547	
of FAMEs were extracted using R-based script MetabQ53. Absolute quantities of fatty 548	
acids were calculated using the calibration curves. 549	
 550	
Liquid Chromatography/Mass Spectrometry analyses 551	
Plasma and CSF samples were diluted 50-fold with cold solvent, comprising 50% 552	
methanol, 30% acetonitrile, 20% water. Free fatty acids and fatty acid precursors were 553	
extracted from CNS and bone marrow cells, and from 1x106 cells from in vitro culture, 554	
by resuspending cells in 1mL of the same solvent. Samples were vortexed for 15min 555	
and then centrifuged at 16,100 x g for 10 minutes at 0-4°C. Supernatants were 556	




Total fatty acids were extracted from 1x106 in vitro cultured cells. For lipid 559	
saponification, cells were resuspended in 1 mL of 90% methanol in water containing 560	
0.3M of potassium hydroxide, followed by vortexing and incubation at 80ºC for 60 561	
minutes. Samples were then brought to room temperature and 100 µL of formic acid 562	
and 800 µL of hexane were added to each sample. After vortexing, the upper phase 563	
was transferred into a glass HPLC vial, and samples were re-extracted with 700 µL of 564	
hexane. The upper phase was again collected and pooled with previously collected 565	
volume. Samples were dried under nitrogen, reconstituted in 200 µL of methanol, and 566	
stored at -80°C until LC-MS analysis. Fatty acids were analyzed by a QExactive 567	
Orbitrap mass spectrometer (Thermo Scientific, Waltham, MA, USA) together with a 568	
Thermo Ultimate 3000 HPLC system. The HPLC setup consisted of a HSS T3 column 569	
(150 x 2.1 mm, 1.8 µm, Waters Corporation, Milford, MA, USA), with a HSS T3 guard 570	
column (Waters, 1.8 µm) and an initial mobile phase of 80% 0.1% formic acid in water/ 571	
20% 0.1% formic acid in acetonitrile. Samples (5 µl) were injected and metabolites were 572	
separated over a 7 minutes mobile phase gradient, increasing the organic mobile phase 573	
(0.1% formic acid in acetonitrile) to 95%, using a flow rate of 400 µL/min and a column 574	
temperature of 45°C. The total analysis time was 12 minutes. 575	
 576	
For fatty acyl-CoAs extraction, 8x106 cells cultured in vitro were resuspended in 700 µL 577	
of cold methanol (-20ºC). The samples were vigorously vortexed for 60 seconds and put 578	
at -20ºC for 10 minutes. 500 µL of cold (-20ºC) chloroform were added to the tube and 579	
the mixture was vigorously vortexed for 60 seconds. Then, 270 µL of water were added 580	
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to the mixture, the samples were vortexed again and placed on ice for 10 min. Tubes 581	
were centrifuged at 4ºC, 16,100 x g for 15 minutes. 500 µL of the upper layer were 582	
transferred into 1 mL glass vial and gently dried under nitrogen. The dried extracts were 583	
reconstituted in 50 µL of methanol:water (in a proportion of 1:1) and transferred to 584	
HPLC glass vials equipped with 50 µL inserts. Thermo Ultimate 3000 high-performance 585	
liquid chromatography (HPLC) system coupled to Q- Exactive Orbitrap Mass 586	
Spectrometer (Thermo Fisher Scientific) was used with a resolution of 70,000 at 200 587	
mass/charge ratio (m/z), with electrospray ionization. Detection was at positive mode 588	
across a mass range of 600 to 1500 m/z. HPLC setup consisted HSS T3 column (150 x 589	
2.1 mm, 1.8 µm, Waters). 5 µL of biological extracts were injected and the compounds 590	
were separated with mobile phase gradient of 12 min, starting at 90% aqueous (0.5% 591	
Ammonium hydroxide) and 10% organic (Acetonitrile with 0.5% Ammonium hydroxide) 592	
and terminated with 40% organic. Flow rate and column temperature were maintained 593	
at 0.3 mL/min and 30°C, respectively, for a total run time of 18 min. HESI source 594	
parameters: the sheath gas flow rate and the aux gas flow rate were set to 45 and 10 595	
arbitrary units; the spray voltage was 4.5 Kv; The capillary temperature and the aux gas 596	
heater temperature were 300c and 350c respectively; the S-lens RF level was set at 50. 597	
All metabolites were detected using mass accuracy below 5 ppm. Thermo Xcalibur was 598	
used for data acquisition. TraceFinder 4.1 was used for analysis. Peak areas of 599	
metabolites were determined by using the exact mass of the singly charged ions. 600	
 601	




RNA was extracted from cells resuspended and lysed in TRIzol according to 604	
manufacturer’s instructions, and underwent DNase treatment using an RNase-free 605	
DNase kit (Qiagen). RNA quality was assessed with the RNA Nano Chip kit (Agilent) on 606	
an Agilent Bioanalyser 2100. 5 µg of total RNA from each sample was used to 607	
synthesize cDNA using the PrimeScript RT reagent kit (Promega) with oligo-dT primers, 608	
according to the manufacturer’s instructions. Quantitative PCR reactions were 609	
performed with specific primers listed in Supplementary Table 5 and the GoTaq qPCR 610	
master mix kit (Promega) using the Biorad system. Differential expressions of 611	
transcripts of interest were calculated in relation to the human 36B4 housekeeping 612	
transcript for SEM and REH cell line. For 018z cell line, quantitative PCR reactions were 613	
performed with the SYBR™ Green PCR Master Mix (Thermo Fisher) using the 614	
StepOnePlus™ Real-Time PCR System (Applied Biosystems). Human HPRT was used 615	
as a housekeeping gene. 616	
 617	
For patient-derived xenograft samples cDNA was generated using Applied Biosystems 618	
High-Capacity RNA-to-cDNA™ Kit (Thermo Fisher, MA, #4387406). cDNA was 619	
amplified in a sequence-specific manner using a Multiplex PCR kit (Qiagen # 206143), 620	
then treated with Exonuclease I (4U/µL New England Biolabs, MA, #M0293L) to remove 621	
unincorporated primers. Samples and primers were loaded onto a 48.48 Dynamic 622	
Array™ chip. The chip was primed on a Biomark™ IFC controller MX then multiplex 623	
PCR performed using a Biomark™ system for Genetic Analysis (all Fluidigm 624	
Corporation, CA). All steps were performed as per manufacturer’s instructions. Data 625	




RNA sequencing analyses  628	
RNA samples were run on a Next Seq500 Sequencing system (Illumina). The raw fastq 629	
files containing paired-end 2 x 75bp reads were pre-processed to trim the 3’ end 630	
adapter with Cutadapt55 (version 1.5) and to trim the very low quality reads using Sickle 631	
(version 0.940) software (https://github.com/najoshi/sickle) with generous quality 632	
threshold -q 10. Only read pairs containing ≥54 bases were kept. Transcript expression 633	
quantification was performed using Kallisto (version 0.42.4) software56 against 634	
combined human and mouse transcriptomes, Ensembl GRCh38 and GRCm38, 635	
respectively, in order to remove the possible mouse RNA contamination. Read counts 636	
related to human transcripts were collected, rounded, and summarized into gene 637	
specific read counts. These were then processed with DESeq2 software57 to generate 638	
gene expression estimates after regularized log transformation which stabilized 639	
variance as a function of mean. 640	
 641	
Metabolic enrichment 642	
Preprocessed RNA expression data from RNA sequencing was analyzed using single 643	
sample gene set enrichment analysis (ssGSEA). Gene expression signatures for 644	
metabolic pathways were downloaded from the MSIGDB database 645	
(software.broadinstitute.org/gsea/msigdb) and included signatures from the KEGG and 646	
REACTOME pathway databases. For each signature S and each sample, a positive 647	
signature score was calculated together with a p-value pS indicating the significance of 648	
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the score (permutation test, n=10,000). For a given signature S, we calculated the fold 649	
change in the expression of the signature between the two sample groups (CNS, 650	
Spleen) as the difference of the log-transformed p-values ES(sample)=-log2(pS(sample)), 651	
i.e. FC(S)=mean(ES(CNSsamples))-mean(ES(SPLEENsamples)). The fold changes 652	
were plotted in a bar plot. Student’s T-test was used to calculate significance of 653	
differential expression between the groups. Furthermore, a Pre-Ranked GSEA using 654	
fold change values was performed to display the enrichment profiles for several gene-655	
sets (permutation test, n=1,000, classic enrichment statistic). All the regular log-656	
transformed counts of selected genes were double-scaled. The biclustering was 657	
performed using Euclidean distance and complete linkage and the heatmap was made 658	
using the gplots package for R (v. 3.0.1)58. 659	
 660	
For comparison, available human and primograft data was downloaded from the GEO 661	
database (https://www.ncbi.nlm.nih.gov/geo/), Refs. GSE60926 and GSE89710 662	
respectively. Those datasets were analysed using the Affymetrix Transcriptome 663	
Analysis Console v4.0, employing Robust Multiarray Average summarization and the 664	
moderated differential expression analysis was carried out using the empirical Bayes 665	
method with FDR correction.  666	
 667	
Histology 668	
Murine heads and femurs were stripped of soft tissues, fixed in 10% neutral buffered 669	
formalin (CellPath, Powys, United Kingdom), and decalcified in Hilleman and Lee EDTA 670	
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solution (5.5% EDTA in 10% formalin) for 2 to 3 weeks. Following paraffin embedding, 671	
hematoxylin and eosin staining (Sigma-Aldrich) was performed on 5-mm brain/femur 672	
sections. Photographs were taken using an Axio Observer Light microscope (Zeiss). 673	
 674	
Statistical analysis 675	
Parametric data were analyzed using two-sided Student unpaired or paired t-tests. 676	
Nonparametric data were analyzed using two-sided Mann-Whitney U tests. For wet lab 677	
experiments a p value of <0.05 was considered significant. In all figures, data are 678	
presented as Mean ± Standard Deviation (SD). Analysis was carried out using 679	
GraphPad Prism software (La Jolla, CA). 680	
 681	
Data availability 682	
RNA-seq data supporting the findings of this study have been deposited in Gene Bank 683	
(accession numbers: GSE135115; GSE135113; GSE135114). The GSE135115 684	
SuperSeries is entitled "Gene expression profiles of MLL-AF4 and TEL-AML1 acute 685	
lymphoblastic leukaemia blasts retrieved from central nervous system and spleen". This 686	
SuperSeries contains two series related to SEM and REH experiments as follows: 687	
GSE135113 "Gene expression profiles of MLL-AF4 acute lymphoblastic leukaemia 688	
blasts retrieved from central nervous system and spleen", GSE135114 "Gene 689	
expression profiles of TEL-AML1 acute lymphoblastic leukaemia blasts retrieved from 690	
central nervous system and spleen”. The source data associated with each figure is 691	
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provided with the manuscript. All other data supporting the findings of this study is 692	
available from the corresponding author on reasonable request. 693	
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Figure 1. Fatty acid synthesis-related genes are upregulated in CNS-derived ALL 878	
cells in xenograft models. (A) Heatmap representation of hierarchical clustering of 879	
genes differentially expressed between human SEM cells isolated from CNS and spleen 880	
of xenografted mice (n=2 independent groups of 5 mice). (B)I-II Enrichment plots of 881	
metabolism of lipids and lipoproteins (REACTOME) and oxidative phosphorylation 882	
(KEGG) for SEM cell line extracted from the CNS and spleen of xenografted mice. 883	
Profile of the running ES score & Positions of the GeneSet Members on the Rank 884	
Ordered List. III Statistically significant biological functions in SEM cells isolated from 885	
CNS and spleen of xenografted mice. Single sample GSEA scores were calculated for 886	
an array of metabolic gene signatures from MSIGDB, including KEGG, Reactome and 887	
GO term signatures. p-values for positive association with a signature (enrichment) 888	
were calculated by permutation test. Plotted are signatures with significant fold-changes 889	
in enrichment between the CNS versus spleen groups (log2 scale). Red bars indicate 890	
signatures with positive log fold-change (gain) in CNS versus spleen, blue bars indicate 891	
negative log fold-change (loss) in CNS versus spleen samples. (C) Total fatty acid 892	
levels measured by GC-MS in non-leukemic human plasma and CSF samples. n=18. 893	
Bars represent mean +/- SD. #: below detection levels. (D) Total fatty acid levels 894	
measured by GC-MS in non-leukemic murine plasma and paired CSF samples. n=9. 895	













Figure 2. SCD1 is upregulated in primary patient samples in the central nervous 905	
system. (A) Quantitative PCR validation of top ranked genes from RNA-Seq in n=5 906	
patient derived xenografts with t(12;21) ETV6-RUNX1 (TEL-AML1) translocation or 907	
t(4;11) MLL-AFF1 (MLL-AF4)] translocation. Results are normalized to 36B4 human 908	
housekeeping gene and presented as Log2 fold change enrichment comparing CNS to 909	
spleen. p (two tailed) = One sample T and Wilcoxon test. (B) Gene expression of SCD1 910	
from RNAseq data deposited in public databases. Left: Samples of BM of patients at 911	
diagnosis and relapse and CNS at relapse, unpaired analysis. Right: Patient-derived 912	
xenograft samples established by transplantation of patients’ ALL cells onto NSG mice. 913	
SCD1 expression in cells isolated from paired CNS and spleen is shown in the graph. 914	
FDR – False discovery rate. (C) Intracellular staining of SCD1 in cells from the BM 915	
(green) and CNS (grey) of a mouse transplanted with 018z cells. The peaks are relative 916	









Figure 3. SCD1 overexpression confirms a competitive advantage for “SCD1-922	
high” cells in the CNS microenvironment. (A) SCD1 gene expression levels following 923	
SCD1 overexpression in 018z cells. (B) Western blot of SCD1 protein after 924	
overexpression in 018z cells. (C)I-II Ratio of relative levels of oleoyl-CoA/stearoyl-CoA 925	
and of palmitoleoyl-CoA/palmitoyl-CoA in control (CTL) and SCD1-high 018z cells. 926	
p=Student’s t-test. (D) Human leukemia burden in 018z xenograft model. Total amount 927	
of leukemic cells in CNS, BM and spleen of NSG mice xenografted with human 018z 928	
ALL cell line overexpressing SCD1 (SCD1-high) or control (CTL) GFP+ at the time of 929	
sacrifice. (E) Human leukemia burden in REH xenograft model. Total amount of 930	
leukemic cells in CNS, BM and spleen of NSG mice xenografted with human REH ALL 931	
cell lines overexpressing SCD1 (SCD1-high) or control (CTL) GFP+ at the time of 932	
sacrifice. p=paired Student’s t-test. (F) Competition assay in vivo: FACS plots of cells 933	
injected (INPUT) and cells isolated from the CNS of the mice at sacrifice (OUTPUT). 934	
Top: GFP+ control cells transduced with a GFP-carrying lentiviral backbone and 935	
mCherry+ control cells transduced with a mCherry carrying lentiviral backbone injected 936	
in a ratio of 1:1. Bottom: GFP+ SCD1 overexpressing (SCD1-high) cells and mCherry+ 937	
control cells transduced with a mCherry carrying lentiviral backbone injected in a ratio of 938	
1:1. (G) Ratio of total number of SCD1-high 018z cells (GFP+) to control 018z cells 939	
(mCherry+) in CNS, BM and spleen of NSG mice transplanted with a mixture of the two 940	
cell types in a ratio of 1:1. The backbone vector for SCD1 overexpression was used as 941	












Figure 4. SCD1 ablation decreases 018z cells engraftment in the CNS. (A) Western 950	
blot analysis of SCD1 after CRISPR-Cas9 gene ablation in 018z cells. Each lane 951	
represents a different gRNA used for the initial screening. gRNA4 decreased SCD1 952	
protein expression while gRNA1-3 did not affect its levels. (B) Gene expression level of 953	
SCD1 after CRISPR-Cas9 knockout in 018z cells by gRNA4. (C)I-II Ratio of relative 954	
levels of oleoyl-CoA/stearoyl-CoA and of palmitoleoyl-CoA/palmitoyl-CoA in control 955	
(CTL) and SCD1-low 018z cells. p=Student’s t-test (D) In vitro proliferation of SCD1-low 956	
and control (CTL) 018z cells after 96 hours in in medium supplemented with 10% 957	
lipidated or delipidated FBS. The dotted line represents the initial number of cells plated 958	
at T0. p=two-way ANOVA. (E) Human leukemia burden in 018z xenograft model. Total 959	
amount of leukemic cells in CNS, BM and spleen of NSG mice xenografted with human 960	
018z ALL cell lines SCD1-low or control GFP at the time of sacrifice. p=paired Student’s 961	
t-test. (F) Intracellular staining of SCD1 in human cells isolated from the BM of mice 962	
transplanted with SCD1-low and control (CTL) 018z cells. The scramble vector for 963	
SCD1 downregulation was used as control vector. The peaks are relative to the 964	










Figure 5. SCD1 pharmacological inhibition decreases 018z cells engraftment in 970	
the CNS. In vitro proliferation of “SCD1-high”, “SCD1-low” and matching control (CTL) 971	
018z cells after seeding 0.5x106 cells/well for 96 hours in medium supplemented with 972	
10% lipidated (A-B) or delipidated (C-D) FBS treated with 1µM of the SCD1 inhibitor 973	
SW203668 or vehicle (DMSO).The dotted line represents the initial number of cells 974	
plated at T0. p=two-way ANOVA. (D) GFP+mCherry+FFLuc+ 018z cells were injected 975	
intravenously to NSG mice and treated from day 1 to day 10 with the SCD1 inhibitor 976	
SW203668 or vehicle (n=5 group). Representative bioluminescence of the tumor load at 977	
the time of sacrifice in three different pairs of mice, top: vehicle treated mice; bottom: 978	
drug treated mice. Decrease in the tumor load is clear in the spine and the skull area 979	
(CNS – marked with white box). Total amount of leukemic cells in CNS (E) and BM (F) 980	
of NSG mice xenografted with human GFP+mCherry+FFLuc+ 018z and treated with 981	
SW203668 for 10 days at the time of sacrifice. The backbone vector for SCD1 982	
overexpression was used as control vector for SCD1-high and the scramble vector was 983	























Figure 6. SCD1 pharmacological inhibition decreases patient-derived xenograft 1001	
(PDXs) engraftment in the CNS. Human leukemia burden in PDXs. Cells from 4 1002	
different PDXs were injected intravenously into NSG mice. Xenografted mice were 1003	
treated daily from day 7 with the SCD1 inhibitor SW203668 or vehicle (n=5 group) at 20 1004	
mg/kg. The total amounts of leukemic cells in CNS and BM of NSG mice at the time of 1005	





Table 1. Precursors for de novo fatty acid synthesis in mice. 1008	
 1009	
Table 1. LC-MS quantification of key nutrients extracted from CSF and plasma of 1010	
healthy (Control, n=8) and NSG mice and mice transplanted with the SEM cell 1011	
line at clinical endpoint (n=6).	1012	
